A phase II study of percutaneous radiofrequency ablation for malignant reanl tumor (JIVROSG-0701) - Percutaneous radiofrequency ablation for malignant renal tumor (JIVROSG-0701)

Japan Interventional Radiology in Oncology Study Group (JIVROSG)0 个研究点目标入组 33 人开始时间: 2008年4月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Cardiac pacemaker. 2) Artery, nerve or ureter exists on the puncture route. 3) Target lesion adjacent to renal pelvis, or a RFA needle can not be inserted without passing through renal pelvis or alimentary tract. 4) Non-mesurable target lesion on CT. 5) Colinically significant bleeding tendency or abnormal coagulation. 6) Tentative stop of anti-platelet or anti-coagulant medication is not allowed. 7) Drug allergy 8) With active infection 9) With active inflammation 10) Fever above 38 degrees Celsius. 11) If having multiple lesions, no treatment of tumors except a target lesion for 4 weeks after the treatment for a target lesion is not allowed. 12) Stop of chemotherapy or immunotherapy for 4 weeks after the treatment for a target lesion is not allowed. 13) Previous reginal therapy for the target lesion. 14) Pregnancy.

发起方

Japan Interventional Radiology in Oncology Study Group (JIVROSG)